A Phase 2 interventional study of Rozanolixizumab and Placebo in Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis, sponsored by UCB Biopharma SRL. Terminated at 27 sites in 9 countries. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Autoimmune Diseases of the Nervous System with a site in United States — 7 open to participants now, 10 under way, 2 of them phase 3. Autoimmune Diseases of the Nervous System · United States.
Among the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is one of 7 that started in 2021, is one of 9 in phase 2, and was the 15th registered.
123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.
Browse Autoimmune Diseases of the Nervous System studies →7 of the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States are open now. Recruiting first, the newest first:
University of Texas at Austin · Sites in United States
Ages 18–80
Autoimmune Neurology Alliance · Sites in United States
Ages 18+
Kite, A Gilead Company · Sites in United States
Ages 18+
Brain Inflammation Collaborative · Sites in United States
Ages 2+ · Healthy volunteers
University of Utah · Sites in United States, Netherlands, Spain
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 40 across 63 interventional studies indexed under Autoimmune Diseases of the Nervous System.
Median enrollment 53 across the 21 interventional studies, 311 across the 7 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
UCB S.A. has 1 study filed under Autoimmune Diseases of the Nervous System — fewer than ten, so there is no comparison to draw.
1 of the studies in Autoimmune Diseases of the Nervous System with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05503264Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | 2026-12-16 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy of rozanolixizumab as measured by seizure freedom, change in cognitive function, use of rescue medication, onset of seizure freedom and to assess safety and tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study participant must have ≥2 seizures/week during the Screening Period or have experienced such seizures that stopped following high dose (500 to 1000 milligram (mg) methylprednisolone (MP) equivalent/day):
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
i) Not a woman of (WOCBP) OR ii) A WOCBP who agrees to follow the guidance during the treatment period and for at least 90 days after the final dose of study treatment
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive a predefined dose of rozanolixizumab.
Drug: Rozanolixizumab
Participants will be randomized to receive a dose of placebo.
Drug: Placebo
* Pharmaceutical form: Solution for infusion * Route of administration: Subcutaneous use Subjects will receive rozanolixizumab in a pre-specified sequence during the Treatment Period.
* Pharmaceutical form: Solution for infusion * Route of administration: Subcutaneous use Subjects will receive placebo in a pre-specified sequence during the Treatment Period.
Number of Seizure Free Study Participants at the End of the Treatment
Seizure freedom was defined as a minimum of 28 consecutive days of no seizures of any type during the treatment and maintained until the end of the treatment (Week 25).
Time frame: From Baseline until the end of the Treatment (Week 25)
Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of 12 subtests that contribute to 5 age-based domain index scores (immediate memory, visuospatial/constructional, language, attention, delayed memory) that were aggregated for a total scale index score. All index scores have an age-based mean of 100, with a standard deviation (SD) of 15. The total scale score was calculated by taking the mean of the sum of the five index scores. Total possible scale index scores range from 40-135. Higher scores reflect better neurocognitive performance. The total scale index score is the score typically used to reflect global neurocognitive status. Baseline of RBANS is defined as the screening (Visit 1, Week -1) value.
Time frame: From Baseline to Week 5, 13, 21 and 25
Percentage of Participants With a Favorable Outcome in the Modified Rankin Scale (mRS) During the Treatment
Percentage of participants with a favorable outcome in mRS during treatment, where favorable outcome defined as no worsening for participants with Baseline mRS score of ≤1 or improvement of ≥1 point for participants with Baseline mRS score of ≥2. The mRS is commonly used scale for measuring degree of disability or dependence in daily activities of people who suffered a stroke or other causes of neurological disability. The scale ranges from 0 (perfect health) to 6 (death). 0-No symptoms at all 1. No significant disability despite symptoms; able to carry out all usual activities 2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. Moderate disability; requiring some help, but able to walk without assistance 4. Moderately severe disability; unable to walk and attend to own bodily needs without assistance 5. Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. Dead
Time frame: From Baseline until the end of the Treatment (Week 25)
Number of Participants Who Required Rescue Medication Due to an Absence or Loss of Clinical Benefit During the Treatment
Study participants who required rescue medication due to an absence or loss of clinical benefit were discontinued blinded treatment and completed the assessments for the early discontinuation visit.
Time frame: From Baseline until the end of the Treatment (Week 25)
Time to First Occurrence of Seizure Freedom During the Treatment
The time to first occurrence of seizure freedom was defined by the number of days after randomization to the first day of the first 28 consecutive days without seizures during the treatment. Time to first occurrence of 28 consecutive days of seizure freedom (days) during the treatment was calculated as date of first day of occurrence of 28 consecutive days of seizure freedom - Date of Randomization + 1.
Time frame: From Baseline until the end of the Treatment (Week 25)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP, whether or not related to the IMP. A TEAE was defined as an AE starting on or after the time of first administration of IMP or any unresolved event already present before the first administration of IMP that worsens in intensity following exposure to treatment up to the end of the Treatment and including the 8-week (56 days) Safety-Follow Up (SFU).
Time frame: From Baseline until the End of Study (Week 32)
The study started to enroll participants in September 2021 and concluded in April 2024.
| Milestone | Placebo | Rozanolixizumab (RLZ) |
|---|---|---|
| Started | 6 | 6 |
| Completed | 2 | 0 |
| Not completed | 4 | 6 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Permanently left due to seizure recurrence | 1 | 0 |
| Withdrew: Relapse with insults | 0 | 1 |
| Withdrew: Permanently left due to new seizure recurrence | 0 | 1 |
Seizure freedom was defined as a minimum of 28 consecutive days of no seizures of any type during the treatment and maintained until the end of the treatment (Week 25).
| Participants | Placebo | Rozanolixizumab (RLZ) |
|---|---|---|
| Number of Seizure Free Study Participants at the End of the Treatment | 1 | 0 |
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of 12 subtests that contribute to 5 age-based domain index scores (immediate memory, visuospatial/constructional, language, attention, delayed memory) that were aggregated for a total scale index score. All index scores have an age-based mean of 100, with a standard deviation (SD) of 15. The total scale score was calculated by taking the mean of the sum of the five index scores. Total possible scale index scores range from 40-135. Higher scores reflect better neurocognitive performance. The total scale index score is the score typically used to reflect global neurocognitive status. Baseline of RBANS is defined as the screening (Visit 1, Week -1) value.
| score on a scale | Placebo | Rozanolixizumab (RLZ) |
|---|---|---|
| Week 5 | 4.5 ± 2.6 | 2.2 ± 11.3 |
| Week 13 | 7.0 ± 2.9 | 12.3 ± 7.9 |
| Week 21 | 7.0 ± 7.3 | NA ± NA |
| Week 25 | NA ± NA | NA ± NA |
Percentage of participants with a favorable outcome in mRS during treatment, where favorable outcome defined as no worsening for participants with Baseline mRS score of ≤1 or improvement of ≥1 point for participants with Baseline mRS score of ≥2. The mRS is commonly used scale for measuring degree of disability or dependence in daily activities of people who suffered a stroke or other causes of neurological disability. The scale ranges from 0 (perfect health) to 6 (death). 0-No symptoms at all 1. No significant disability despite symptoms; able to carry out all usual activities 2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. Moderate disability; requiring some help, but able to walk without assistance 4. Moderately severe disability; unable to walk and attend to own bodily needs without assistance 5. Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. Dead
| percentage of participants | Placebo | Rozanolixizumab (RLZ) |
|---|---|---|
| Percentage of Participants With a Favorable Outcome in the Modified Rankin Scale (mRS) During the Treatment | NA | NA |
Study participants who required rescue medication due to an absence or loss of clinical benefit were discontinued blinded treatment and completed the assessments for the early discontinuation visit.
| Participants | Placebo | Rozanolixizumab (RLZ) |
|---|---|---|
| Number of Participants Who Required Rescue Medication Due to an Absence or Loss of Clinical Benefit During the Treatment | 3 | 2 |
The time to first occurrence of seizure freedom was defined by the number of days after randomization to the first day of the first 28 consecutive days without seizures during the treatment. Time to first occurrence of 28 consecutive days of seizure freedom (days) during the treatment was calculated as date of first day of occurrence of 28 consecutive days of seizure freedom - Date of Randomization + 1.
| Weeks | Placebo | Rozanolixizumab (RLZ) |
|---|---|---|
| Time to First Occurrence of Seizure Freedom During the Treatment | 0.1 (0.1 to 8.4) | 0.1 (0.1 to 8.3) |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP, whether or not related to the IMP. A TEAE was defined as an AE starting on or after the time of first administration of IMP or any unresolved event already present before the first administration of IMP that worsens in intensity following exposure to treatment up to the end of the Treatment and including the 8-week (56 days) Safety-Follow Up (SFU).
| percentage of participants | Placebo | Rozanolixizumab (RLZ) |
|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 100 | 100 |
Collected over From Baseline until the End of Study (up to Week 32). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Rozanolixizumab (RLZ) | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Event | Placebo | Rozanolixizumab (RLZ) |
|---|---|---|
| COVID-19Infections and infestations | 0/6 | 1/6 |
| Psoas abscessInfections and infestations | 1/6 | 0/6 |
| BacteraemiaInfections and infestations | 0/6 | 1/6 |
| Encephalitis autoimmuneNervous system disorders | 1/6 | 0/6 |
| Peripheral sensory neuropathyNervous system disorders | 1/6 | 0/6 |
| ManiaPsychiatric disorders | 0/6 | 1/6 |
| Suicidal ideationPsychiatric disorders | 0/6 | 1/6 |
| Deep vein thrombosisVascular disorders | 1/6 | 0/6 |
| Event | Placebo | Rozanolixizumab (RLZ) |
|---|---|---|
| Oedema peripheralGeneral disorders | 0/6 | 4/6 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 3/6 |
| Influenza like illnessGeneral disorders | 2/6 | 0/6 |
| Alanine aminotransferase increasedInvestigations | 0/6 | 2/6 |
| InsomniaPsychiatric disorders | 1/6 | 2/6 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 2/6 | 0/6 |
| LymphopeniaBlood and lymphatic system disorders | 1/6 | 1/6 |
| Lacrimation increasedEye disorders | 1/6 | 0/6 |
| Vision blurredEye disorders | 1/6 | 1/6 |
| Abdominal painGastrointestinal disorders | 0/6 | 1/6 |
Baseline Characteristics refer to the Randomized Set (RS) which consisted of all enrolled study participants who were randomized to treatment arms.
| Age, Continuous(Years) | Placebo | Rozanolixizumab (RLZ) | Total |
|---|---|---|---|
| Mean | 60.7 ± 12.4 | 70.7 ± 11.4 | 65.7 ± 12.5 |
| Age, Customized(Participants) | Placebo | Rozanolixizumab (RLZ) | Total |
|---|---|---|---|
| 18 - <65 years | 3 | 1 | 4 |
| 65 - <85 years | 3 | 5 | 8 |
| >=85 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo | Rozanolixizumab (RLZ) | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 4 | 4 | 8 |
| Race/Ethnicity, Customized(Participants) | Placebo | Rozanolixizumab (RLZ) | Total |
|---|---|---|---|
| White | 5 | 4 | 9 |
| Missing | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Placebo | Rozanolixizumab (RLZ) | Total |
|---|---|---|---|
| Not Hispanic or Latino | 5 | 4 | 9 |
| Missing | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Sep 2021 to primary completion in Mar 2024, 29 months.
Results were first posted in May 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rozanolixizumab
Autoimmune Diseases of the Nervous System →